Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
Joanna Moes-SosnowskaIwona K RzepeckaJoanna ChodzynskaAgnieszka Dansonka-MieszkowskaLukasz Michael SzafronAneta BalabasRenata LotockaPiotr SobiczewskiJolanta KupryjanczykPublished in: Cancer biology & therapy (2019)
Our study shows for the first time that FANCD2 overexpression is a strong negative prognostic factor in ovarian cancer, particularly in patients treated with TP regimen. Moreover, increased mRNA level of the BRIP1 is a negative prognostic factor in the PC-treated patients. Next, changes in the BRCA2 and BRIP1 genes are rare and together with other analyzed FA genes considered as homologous recombination deficiency may not affect the expression level of analyzed genes.
Keyphrases
- prognostic factors
- genome wide
- poor prognosis
- bioinformatics analysis
- genome wide identification
- dna repair
- binding protein
- dna damage
- breast cancer risk
- end stage renal disease
- newly diagnosed
- cell proliferation
- transcription factor
- ejection fraction
- chronic kidney disease
- dna methylation
- gene expression
- high grade
- oxidative stress
- replacement therapy
- smoking cessation